News | November 04, 2023
Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr
Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
Subscribe To Our Newsletter & Stay Updated
